6078 Background: We analyzed the pattern of prostate cancer related and unrelated resource use (RU) after radical prostatectomy (RP) in a long-term cohort of men with prostate cancer (CaP). Methods: From the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a national disease registry of men with prostate cancer, we identified 1,865 men treated with RP for clinically localized disease between 1999–2002. RU questionnaires were completed at the time of RP, representing all RU for 6 months perioperatively, and at 6 month intervals thereafter. We assessed RU by 6 month time periods for office visits, hospitalizations, emergency room visits, outpatient procedures, medications, diagnostic tests, and medical supplies. Data from 1,427 patients who completed at least one questionnaire in the 24 months following RP were analyzed. RU was defined as related or unrelated to CaP. The percent and mean of each type of RU was determined at RP to serve as a baseline and at 6, 12, 18, and 24 months after RP. Data collected at each time point represents RU in the preceding 6 months. Results: Most patients were Caucasian, age 60–69, with 1–2 comorbidities. 53% were diagnosed with low risk prostate cancer (PSA <10, Gleason sum <7, T-stage 1–2a). Generally, we found overall RU related to CaP was highest at RP but decreased rapidly by 6 months when CaP related RU became stable. Conversely, RU unrelated to CaP showed a stable pattern at all time points. For example, at the RP six month time period, mean CaP related office visits was 4.0 vs. 0.9 at 24 months. In contrast, office visits unrelated to CaP remained constant (mean 3.9 at RP and 4.1 at 24 months.) CaP related hospitalizations, ER visits and outpatient procedures were uncommon. Medication use was consistent over time: a mean of 0.5 CaP related vs. 2.6 unrelated medications at RP compared to 0.5 and 3.0 at 24 months, respectively. Diagnostic testing related to CaP decreased from 54% at RP to 7% at 24 months. Conclusions: Overall prostate cancer disease burden after RP is high but short term. Unlike unrelated RU, prostate cancer related RU rapidly decreases by 6 months postoperatively, although it continues up to 24 months at a much lower level. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration TAP Imetrikus, Merck AstraZeneca, Pfizer TAP